Comparative Adverse Event Reporting Patterns of Amoxicillin and Amoxicillin/Clavulanic Acid in FAERS: A 2022–2025 Disproportionality Analysis
Abstract
Amoxicillin, alone or combined with clavulanic acid, is widely used for the treatment of bacterial infections. While clavulanic acid expands amoxicillin's antibacterial spectrum by inhibiting β‐lactamases, differences in their real‐world safety profiles and reporting patterns remain relevant for pharmacovigilance and antimicrobial surveillance. This study aimed to characterize and compare adverse event reporting associated with amoxicillin and amoxicillin/clavulanic acid and to explore reporting signals involving Preferred Terms potentially associated with reduced treatment effectiveness.